T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1151
Capital Southwest
CSWC
$1.61B
| $17.6M | ﹤0.01% |
1,330,647
-6,401
| -0.5% | -$82.6K |
|
|
SHOR
1152
DELISTED
ShoreTel, Inc.
SHOR
| $17.6M | ﹤0.01% |
2,697,352
+80,650
| +3% | +$580K |
|
1153
Antero Resources
AR
$11.3B
| $17.6M | ﹤0.01% |
267,612
-32,353
| -11% | -$2.05M |
|
1154
Lincoln Electric
LECO
$15.6B
| $17.5M | ﹤0.01% |
249,991
+15,308
| +7% | +$1.04M |
|
1155
Clarus
CLAR
$141M
| $17.5M | ﹤0.01% |
1,563,248
+10,748
| +0.7% | +$120K |
|
1156
Sprott Physical Gold and Silver Trust
CEF
$8.17B
| $17.4M | ﹤0.01% |
1,194,070
+8,500
| +0.7% | +$117K |
|
1157
Sixth Street Specialty
TSLX
$1.79B
| $17.4M | ﹤0.01% |
+795,240
| New | +$15M |
|
1158
Hooker Furnishings Corp
HOFT
$158M
| $17.3M | ﹤0.01% |
1,073,390
+7,400
| +0.7% | +$108K |
|
1159
NVIDIA
NVDA
$5.46T
| $17.3M | ﹤0.01% |
37,254,240
+879,200
| +2% | +$411K |
|
1160
Ameren
AEE
$30.1B
| $17.2M | ﹤0.01% |
419,709
+8,500
| +2% | +$339K |
|
1161
Cousins Properties
CUZ
$4.93B
| $17.1M | ﹤0.01% |
487,345
-889,521
| -65% | -$29.8M |
|
|
SNMX
1162
DELISTED
Senomyx, Inc.
SNMX
| $16.9M | ﹤0.01% |
1,948,165
-36,500
| -2% | -$304K |
|
|
DDC
1163
DELISTED
Dominion Diamond Corporation
DDC
| $16.8M | ﹤0.01% |
1,160,045
+2,363
| +0.2% | +$30.8K |
|
1164
Energy Recovery
ERII
$397M
| $16.8M | ﹤0.01% |
3,408,063
+7,900
| +0.2% | +$40.8K |
|
|
MHR
1165
DELISTED
MAGNUM HUNTER RESOURCES CORP (DEL)
MHR
| $16.6M | ﹤0.01% |
2,024,560
-896,220
| -31% | -$7.3M |
|
|
PTLA
1166
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $16.6M | ﹤0.01% |
567,579
-157,956
| -22% | -$3.82M |
|
1167
CBRE Group
CBRE
$44B
| $16.4M | ﹤0.01% |
512,245
+21,710
| +4% | +$627K |
|
|
EPZM
1168
DELISTED
Epizyme, Inc
EPZM
| $16.3M | ﹤0.01% |
+524,531
| New | +$12.4M |
|
1169
Utah Medical Products
UTMD
$230M
| $16.3M | ﹤0.01% |
317,190
+31,787
| +11% | +$1.63M |
|
1170
PRA Group
PRAA
$762M
| $16.3M | ﹤0.01% |
273,850
+19,300
| +8% | +$1.1M |
|
|
SIX
1171
DELISTED
Six Flags Entertainment Corp.
SIX
| $16.3M | ﹤0.01% |
382,200
+29,200
| +8% | +$1.19M |
|
1172
MaxLinear
MXL
$6.95B
| $16.3M | ﹤0.01% |
1,614,317
+6,500
| +0.4% | +$59.6K |
|
|
NPSP
1173
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $16.2M | ﹤0.01% |
491,300
+23,900
| +5% | +$690K |
|
|
CRRC
1174
DELISTED
COURIER CORP
CRRC
| $16.2M | ﹤0.01% |
1,086,860
+5,850
| +0.5% | +$81.4K |
|
|
JWN
1175
DELISTED
Nordstrom
JWN
| $16M | ﹤0.01% |
235,529
+1,080
| +0.5% | +$70.1K |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.